Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | PNMT | P11086 | 2/20 | 0.75 |
| ▸ | CD44 | P16070 | 1/20 | 0.75 |
| ▸ | MAOB | P27338 | 1/20 | 0.75 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | DRD1 | P21728 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD5 | P21918 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.48 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.48 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.48 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.48 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.48 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23555058 | 0.97 | HTR2C (0.94) | HTR2CPNMTCD44MAOBDRD2 | |
| Ammonia Solution, Strong SCHEMBL20359164 | 0.97 | HTR2C (0.94) | HTR2CPNMTCD44MAOBDRD2 | |
| Hydrochloric Acid SCHEMBL2307798 | 0.97 | HTR2C (0.94) | HTR2CPNMTCD44MAOBDRD2 | |
| Hydrochloric Acid SCHEMBL12505041 | 0.94 | HTR2C (0.89) | HTR2CPNMTCD44MAOBDRD2 | |
| Hydrochloric Acid SCHEMBL12803776 | 0.92 | HTR2C (0.84) | HTR2CPNMTCD44MAOBDRD2 | |
| Methyl Alcohol SCHEMBL12803778 | 0.89 | HTR2C (0.80) | HTR2CPNMTCD44MAOBDRD2 | |
| SCHEMBL4503593 | 0.89 | HTR2C (0.80) | HTR2CPNMTCD44MAOBDRD2 | |
| SCHEMBL4502828 | 0.87 | HTR2C (0.76) | HTR2CPNMTCD44MAOBDRD2 | |
| Pyrazine SCHEMBL6434305 | 0.87 | HTR2C (0.76) | HTR2CPNMTCD44MAOBDRD2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL27831591 | 0.87 | PNMT (0.91) | HTR2CPNMTCD44MAOBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | claimed |
| CN-110248926-B | LSD1 inhibitor and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-12-06 | — | — | CN | claimed |
| US-10738030-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-08-11 | — | — | US | claimed |
| US-20190055220-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2019-02-21 | — | — | US | claimed |
| EP-3436446-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2019-02-06 | — | — | EP | claimed |
| CN-105693610-B | The preparation method of lorcaserin intermediate | 国药集团宜宾制药有限责任公司 | 2019-01-11 | — | — | CN | claimed |
| EP-3324950-A1 | TREATMENT FOR VITILIGO | Glaxo Group Limited (GB) | 2018-05-30 | — | — | EP | claimed |
| WO-2017173274-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-05 | — | — | WO | claimed |
| WO-2017017571-A1 | TREATMENT FOR VITILIGO | GLAXO GROUP LIMITED (GB) | 2017-02-02 | — | — | WO | claimed |
| WO-2016069875-A1 | COMPOSITIONS AND METHODS FOR CEASING TOBACCO SMOKING | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-06 | — | — | WO | claimed |
| WO-1993017012-A1 | 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | NOVO NORDISK A/S (DK) | 1993-09-02 | — | — | WO | claimed |
| US-5084453-A | Antibiotics, bactericides | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-01-28 | — | — | US | claimed |
| US-5025009-A | Treatment of central nervous system disorders; bioavailability | NOVO NORDISK A/S (DK) | 1991-06-18 | — | — | US | claimed |
| US-5010074-A | Treating CNS disorders; dopamine antagonist; bioavailability | NOVO NORDISK A/S (DK) | 1991-04-23 | — | — | US | claimed |
| EP-0347672-A1 | Benzazepine derivatives | NOVO NORDISK A/S (DK) | 1989-12-27 | — | — | EP | claimed |
| US-4751222-A | 2,3,4,5-tetrahydro-1H-3-benzazepines and CNS affecting use thereof | NOVO INDUSTRI A/S (DK) | 1988-06-14 | — | — | US | claimed |
| EP-0127423-B1 | 1-(4'-BRANCHED ALKYLSULFONYLPHENYL)-6-CHLORO-7,8-DIHYDROXY-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES | SMITHKLINE BECKMAN CORPORATION (US) | 1988-02-03 | — | — | EP | claimed |
| EP-0200455-A2 | 2,3,4,5-tetrahydro-1H-3-benzazepines substituted in position 5 | NOVO NORDISK A/S (DK) | 1986-11-05 | — | — | EP | claimed |
| EP-0153400-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1985-09-04 | — | — | EP | claimed |
| WO-1985000808-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS AND COMPOSITIONS | SCHERING CORP. (US) | 1985-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738030-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | HTR2C 4509/4885PNMT 4206/4885CD44 3886/4885 |
| US-20190055220-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | HTR2C 4509/4885PNMT 4206/4885CD44 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.